{"id":70287,"date":"2026-07-20T14:26:54","date_gmt":"2026-07-20T06:26:54","guid":{"rendered":"https:\/\/flcube.com\/?p=70287"},"modified":"2026-07-20T14:26:56","modified_gmt":"2026-07-20T06:26:56","slug":"cansino-biologics-secures-nmpa-acceptance-for-menhycia-age-expansion-to-adolescents-extending-chinas-first-quadrivalent-meningococcal-conjugate-vaccine-coverage-to-ages-3-months-17-years","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70287","title":{"rendered":"CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China&#8217;s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months\u201317 Years"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CanSino Biologics Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6185:HKG\">HKG: 6185<\/a>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has <strong>accepted its application<\/strong> to expand the indicated age group for its <strong>Group ACYW135 Meningococcal Conjugate Vaccine (CRM197 Vector)<\/strong> (&#8220;<strong>MCV4<\/strong>&#8220;, trade name: <strong>Menhycia<\/strong>). The proposed expansion will extend coverage from &#8220;<strong>children aged 3 months to 6 years (83 months)<\/strong>&#8221; to &#8220;<strong>individuals aged 3 months to 17 years<\/strong>&#8220;, significantly broadening the vaccine&#8217;s addressable population.<\/p>\n\n\n\n<h2 id=\"h-regulatory-development-timeline\" class=\"wp-block-heading\">Regulatory Development Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Date<\/th><th>Age Range Approved<\/th><\/tr><\/thead><tbody><tr><td><strong>Initial Marketing Approval<\/strong><\/td><td>December 2021<\/td><td>Not specified in announcement<\/td><\/tr><tr><td><strong>First Age Expansion<\/strong><\/td><td>February 2026<\/td><td>3 months to 6 years (83 months)<\/td><\/tr><tr><td><strong>Current Application Acceptance<\/strong><\/td><td>19 Jul 2026<\/td><td><strong>3 months to 17 years<\/strong> (pending approval)<\/td><\/tr><tr><td><strong>Expected Final Approval<\/strong><\/td><td>Q4 2026 (estimated)<\/td><td>Pending NMPA review completion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-market-significance\" class=\"wp-block-heading\">Product Profile &amp; Market Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Product Name:<\/strong> Menhycia (MCV4)<\/li>\n\n\n\n<li><strong>Technology Platform:<\/strong> CRM197 carrier protein conjugate vaccine<\/li>\n\n\n\n<li><strong>Serogroups Covered:<\/strong> A, C, Y, and W135 meningococcal strains<\/li>\n\n\n\n<li><strong>Market Position:<\/strong> <strong>China&#8217;s first quadrivalent meningococcal conjugate vaccine<\/strong><\/li>\n\n\n\n<li><strong>Current Indication:<\/strong> Children aged 3 months to 6 years (83 months)<\/li>\n\n\n\n<li><strong>Proposed Indication:<\/strong> Individuals aged 3 months to 17 years<\/li>\n\n\n\n<li><strong>Target Population Expansion:<\/strong> Increases addressable market by approximately <strong>2.5x<\/strong>, adding adolescents aged 7-17 years<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-epidemiological-rationale-amp-public-health-impact\" class=\"wp-block-heading\">Epidemiological Rationale &amp; Public Health Impact<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Age Group<\/th><th>Meningococcal Disease Risk<\/th><th>Current Vaccination Gap<\/th><th>Menhycia Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Infants (3-12 months)<\/strong><\/td><td>Highest incidence globally<\/td><td>Previously covered<\/td><td>Maintained protection<\/td><\/tr><tr><td><strong>Young Children (1-6 years)<\/strong><\/td><td>Elevated risk period<\/td><td>Currently covered<\/td><td>Continued coverage<\/td><\/tr><tr><td><strong>School-Age Children (7-12 years)<\/strong><\/td><td>Moderate risk; school transmission<\/td><td><strong>Previously uncovered<\/strong><\/td><td><strong>New protection<\/strong><\/td><\/tr><tr><td><strong>Adolescents (13-17 years)<\/strong><\/td><td>Second peak incidence; social mixing<\/td><td><strong>Previously uncovered<\/strong><\/td><td><strong>Critical gap addressed<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-competitive-landscape-analysis\" class=\"wp-block-heading\">Competitive Landscape Analysis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Status in China<\/th><th>Age Range<\/th><th>Key Limitations<\/th><\/tr><\/thead><tbody><tr><td><strong>CanSino Biologics<\/strong><\/td><td>Menhycia (MCV4)<\/td><td><strong>Approved + expanding<\/strong><\/td><td>3m-6y \u2192 <strong>3m-17y<\/strong><\/td><td>Market leader; first-mover advantage<\/td><\/tr><tr><td><strong>Pfizer<\/strong><\/td><td>Nimenrix (MCV4)<\/td><td>Not approved<\/td><td>Global: 6w+<\/td><td>No China market access<\/td><\/tr><tr><td><strong>GSK<\/strong><\/td><td>Menveo (MCV4)<\/td><td>Not approved<\/td><td>Global: 2y+<\/td><td>No China market access<\/td><\/tr><tr><td><strong>Domestic Manufacturers<\/strong><\/td><td>Polysaccharide vaccines<\/td><td>Available<\/td><td>Limited age ranges<\/td><td>Inferior immunogenicity vs. conjugate<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-commercial-opportunity-assessment\" class=\"wp-block-heading\">Commercial Opportunity Assessment<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressable Population:<\/strong> Expansion adds ~120 million adolescents (ages 7-17) to existing ~90 million children (ages &lt;7)<\/li>\n\n\n\n<li><strong>Vaccination Rates:<\/strong> Current meningococcal vaccination rates in China estimated at &lt;10% for eligible populations<\/li>\n\n\n\n<li><strong>Premium Pricing:<\/strong> Conjugate vaccines command 3-5x premium over polysaccharide alternatives<\/li>\n\n\n\n<li><strong>Public Procurement:<\/strong> Potential inclusion in expanded national immunization program (NIP) for broader age groups<\/li>\n\n\n\n<li><strong>Revenue Impact:<\/strong> Age expansion could increase annual revenue by \u00a5800 million-\u00a51.2 billion ($110-170 million) at 15-20% penetration<\/li>\n\n\n\n<li><strong>Market Leadership:<\/strong> Solidifies CanSino&#8217;s position as dominant player in China&#8217;s meningococcal vaccine market<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Validation:<\/strong> Demonstrates CanSino&#8217;s regulatory expertise in managing complex vaccine approvals and expansions<\/li>\n\n\n\n<li><strong>Manufacturing Scale:<\/strong> Existing production capacity positioned to meet expanded demand without significant capital investment<\/li>\n\n\n\n<li><strong>International Potential:<\/strong> Success in China&#8217;s large market strengthens foundation for potential global regulatory submissions<\/li>\n\n\n\n<li><strong>Portfolio Diversification:<\/strong> Reduces reliance on COVID-19 vaccine revenue through established routine immunization product<\/li>\n\n\n\n<li><strong>Investor Confidence:<\/strong> Consistent regulatory progress supports long-term growth narrative beyond pandemic-related products<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial prospects for Menhycia. Actual results may differ due to risks including final NMPA approval decisions, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><br><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071900006_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026071900006_c.\"><\/object><a id=\"wp-block-file--media-9a4c1a05-aee9-40bc-997a-416aad439483\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071900006_c.pdf\">2026071900006_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071900006_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9a4c1a05-aee9-40bc-997a-416aad439483\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CanSino Biologics Inc. (HKG: 6185) announced that the National Medical Products Administration (NMPA) has accepted&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[466,884,68,12],"class_list":["post-70287","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cansino-biologics","tag-hkg-6185","tag-pediatric-drugs","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China&#039;s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months\u201317 Years - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CanSino Biologics Inc. (HKG: 6185) announced that the National Medical Products Administration (NMPA) has accepted its application to expand the indicated age group for its Group ACYW135 Meningococcal Conjugate Vaccine (CRM197 Vector) (&quot;MCV4&quot;, trade name: Menhycia). The proposed expansion will extend coverage from &quot;children aged 3 months to 6 years (83 months)&quot; to &quot;individuals aged 3 months to 17 years&quot;, significantly broadening the vaccine&#039;s addressable population.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70287\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China&#039;s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months\u201317 Years\" \/>\n<meta property=\"og:description\" content=\"CanSino Biologics Inc. (HKG: 6185) announced that the National Medical Products Administration (NMPA) has accepted its application to expand the indicated age group for its Group ACYW135 Meningococcal Conjugate Vaccine (CRM197 Vector) (&quot;MCV4&quot;, trade name: Menhycia). The proposed expansion will extend coverage from &quot;children aged 3 months to 6 years (83 months)&quot; to &quot;individuals aged 3 months to 17 years&quot;, significantly broadening the vaccine&#039;s addressable population.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70287\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-20T06:26:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-20T06:26:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70287#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70287\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China&#8217;s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months\u201317 Years\",\"datePublished\":\"2026-07-20T06:26:54+00:00\",\"dateModified\":\"2026-07-20T06:26:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70287\"},\"wordCount\":511,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CanSino Biologics\",\"HKG: 6185\",\"Pediatric drugs\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70287#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70287\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70287\",\"name\":\"CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China's First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months\u201317 Years - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-20T06:26:54+00:00\",\"dateModified\":\"2026-07-20T06:26:56+00:00\",\"description\":\"CanSino Biologics Inc. (HKG: 6185) announced that the National Medical Products Administration (NMPA) has accepted its application to expand the indicated age group for its Group ACYW135 Meningococcal Conjugate Vaccine (CRM197 Vector) (\\\"MCV4\\\", trade name: Menhycia). The proposed expansion will extend coverage from \\\"children aged 3 months to 6 years (83 months)\\\" to \\\"individuals aged 3 months to 17 years\\\", significantly broadening the vaccine's addressable population.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70287#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70287\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70287#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China&#8217;s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months\u201317 Years\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China's First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months\u201317 Years - Insight, China&#039;s Pharmaceutical Industry","description":"CanSino Biologics Inc. (HKG: 6185) announced that the National Medical Products Administration (NMPA) has accepted its application to expand the indicated age group for its Group ACYW135 Meningococcal Conjugate Vaccine (CRM197 Vector) (\"MCV4\", trade name: Menhycia). The proposed expansion will extend coverage from \"children aged 3 months to 6 years (83 months)\" to \"individuals aged 3 months to 17 years\", significantly broadening the vaccine's addressable population.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70287","og_locale":"en_US","og_type":"article","og_title":"CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China's First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months\u201317 Years","og_description":"CanSino Biologics Inc. (HKG: 6185) announced that the National Medical Products Administration (NMPA) has accepted its application to expand the indicated age group for its Group ACYW135 Meningococcal Conjugate Vaccine (CRM197 Vector) (\"MCV4\", trade name: Menhycia). The proposed expansion will extend coverage from \"children aged 3 months to 6 years (83 months)\" to \"individuals aged 3 months to 17 years\", significantly broadening the vaccine's addressable population.","og_url":"https:\/\/flcube.com\/?p=70287","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-20T06:26:54+00:00","article_modified_time":"2026-07-20T06:26:56+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70287#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70287"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China&#8217;s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months\u201317 Years","datePublished":"2026-07-20T06:26:54+00:00","dateModified":"2026-07-20T06:26:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70287"},"wordCount":511,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CanSino Biologics","HKG: 6185","Pediatric drugs","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70287#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70287","url":"https:\/\/flcube.com\/?p=70287","name":"CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China's First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months\u201317 Years - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-20T06:26:54+00:00","dateModified":"2026-07-20T06:26:56+00:00","description":"CanSino Biologics Inc. (HKG: 6185) announced that the National Medical Products Administration (NMPA) has accepted its application to expand the indicated age group for its Group ACYW135 Meningococcal Conjugate Vaccine (CRM197 Vector) (\"MCV4\", trade name: Menhycia). The proposed expansion will extend coverage from \"children aged 3 months to 6 years (83 months)\" to \"individuals aged 3 months to 17 years\", significantly broadening the vaccine's addressable population.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70287#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70287"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70287#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CanSino Biologics Secures NMPA Acceptance for Menhycia Age Expansion to Adolescents, Extending China&#8217;s First Quadrivalent Meningococcal Conjugate Vaccine Coverage to Ages 3 Months\u201317 Years"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70287"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70287\/revisions"}],"predecessor-version":[{"id":70289,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70287\/revisions\/70289"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}